Serum Isoform [−2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2–10 ng/ml: A Multicentric European Study

Authors

Massimo Lazzeri

Published

January 24, 2013

Abstract

Supporters

Support the authors with ResearchCoin

Journal

European Urology

Topics

Medicine

Internal Medicine

Urology

Pulmonary And Respiratory Medicine

Rheumatology

DOI

10.1016/j.eururo.2013.01.011

Serum Isoform [−2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2–10 ng/ml: A Multicentric European Study

Authors

Massimo Lazzeri

Published

January 24, 2013

Abstract

Supporters

Support the authors with ResearchCoin

Journal

European Urology

Topics

Medicine

Internal Medicine

Urology

Pulmonary And Respiratory Medicine

Rheumatology

DOI

10.1016/j.eururo.2013.01.011

Paper

Paper

Paper

Paper

Serum Isoform [−2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2–10 ng/ml: A Multicentric European Study

Abstract

Supporters

Journal

Topics

DOI

Serum Isoform [−2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2–10 ng/ml: A Multicentric European Study

Abstract

Supporters

Journal

Topics

DOI